Literature DB >> 12870445

Technology evaluation: PK1, Pfizer/Cancer Research UK.

Vladimir Bilim1.   

Abstract

Pfizer (formerly Pharmacia) is collaborating with Cancer Research UK in developing PK1 (FCE-28068) for the potential treatment of various cancers. PK1 is an N-(2-hydroxypropyl) methacrylamide (HPMA) co-polymer-doxorubicin conjugate, attached by a peptide linker, which is currently undergoing phase II trials for breast, non-small-cell lung and colon cancers.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12870445

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  6 in total

1.  Advances of cancer therapy by nanotechnology.

Authors:  Xu Wang; Yiqing Wang; Zhuo Georgia Chen; Dong M Shin
Journal:  Cancer Res Treat       Date:  2009-03-31       Impact factor: 4.679

Review 2.  Polymer-drug conjugates: recent development in clinical oncology.

Authors:  Chun Li; Sidney Wallace
Journal:  Adv Drug Deliv Rev       Date:  2008-02-08       Impact factor: 15.470

3.  The Light at the End of the Tunnel-Second Generation HPMA Conjugates for Cancer Treatment.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  Curr Opin Colloid Interface Sci       Date:  2017-07-28       Impact factor: 6.448

4.  Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems.

Authors:  Twan Lammers; Peter Peschke; Rainer Kühnlein; Vladimir Subr; Karel Ulbrich; Peter Huber; Wim Hennink; Gert Storm
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

Review 5.  Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review).

Authors:  Yan-Jun Zhong; Li-Hua Shao; Yan Li
Journal:  Int J Oncol       Date:  2012-12-28       Impact factor: 5.650

6.  Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy.

Authors:  T Lammers; V Subr; P Peschke; R Kühnlein; W E Hennink; K Ulbrich; F Kiessling; M Heilmann; J Debus; P E Huber; G Storm
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.